Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
He will be responsible for ensuring that every dose of medication that ACG Inspection’s pharmaceutical and nutraceutical partners provide is manufactured and delivered exactly as intended
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
The expansion makes Exothera one of the largest viral vector facilities in Europe
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Subscribe To Our Newsletter & Stay Updated
